Storyline
Lilly to pay CSL $100M upfront to license phase 3-stage IL-6 antibody
Eli Lilly is paying $100 million upfront to license CSL’s Phase 3-stage monoclonal antibody targeting IL-6. CSL will retain rights for an end-stage kidney disease indication currently in a Phase 3 trial, while Lilly explores other potential uses; the antibody had previously been explored for organ transplant rejection.
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Eli Lilly is paying $100 million upfront to license CSL’s Phase 3-stage monoclonal antibody targeting IL-6. CSL will retain rights for an end-stage kidney disease indication currently in a Phase 3 trial, while Lilly explores other potential uses; the antibody had previously been explored for organ transplant rejection.
Score total
1.33
Momentum 24h
3
Posts
3
Origins
2
Source types
2
Duplicate ratio
33%
Why now
- Deal announcement centers on immediate $100M upfront payment
- Asset is described as Phase 3-stage, enabling near-term development choices
- CSL’s Phase 3 ESKD program continues as Lilly evaluates additional uses
Why it matters
- A $100M upfront license highlights demand for late-stage immunology assets
- Split rights enable parallel development: CSL in ESKD, Lilly in other uses
- Prior transplant-rejection exploration may shape repositioning strategy
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6
BioPharma Dive · biopharmadive.com · 2026-02-18 16:15 UTC
Eli Lilly is paying $100 million upfront for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
Fierce Biotech · fiercebiotech.com · 2026-02-18 10:42 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)